Dr. Won Jin Ho presented a talk as part of the Immunology Neighborhood Seminar on “Overcoming the tumor immune ...

In the current study, scientists generate and analyze genomic, transcriptomic, and T-cell receptor sequencing data of metastatic PDAC patients to explore molecular and immune differences between ...

New research uncovers how distinct molecular profiles and immune signatures in ... the prognosis of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). PDAC is a highly aggressive ...

Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, per phase 2 trial data. Data from a phase 2 trial (NCT05481463) presented ...

Safety of these combination therapies will continue to be monitored.” Although only a small subset of patients with metastatic PDAC who have microsatellite instability–high or mismatch ...

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Patients with pancreatic ductal adenocarcinoma (PDAC) face a highly unfavorable outcome and have a poor response to standard treatments. Immunotherapy, especially therapy based on natural ...

Search for other works by this author on: ...

Jan. 28, 2025 — Study reveals how immune cells in the gut distinguish between food and harmful pathogens, shedding light on the origins of both food allergies and intestinal ...